Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios

Summary

Scribe Therapeutics, an early-stage biotech developing CRISPR-based therapies for cardiometabolic diseases, is considering an IPO despite having an immature pipeline with its lead program recently approved for first-in-human testing.